Amgen Ends Trials After Deaths

Thousand Oaks biotech Amgen Inc. said it ended clinical studies of a treatment for advanced stomach cancer after an independent data-monitoring committee found an increase in the number of deaths in patients using a combination of the experimental drug, called rilotumumab, and chemotherapy, compared with those who received only chemotherapy treatment, the Wall Street Journal reports.